Drug intelligence / Profile preview

Trivantel

Development stage: Unknown
Lead developer: Agrovet Market
Modality: Small Molecules
Administration: Oral

Overview

Trivantel is a **veterinary antiparasitic small-molecule** product developed and marketed by Agrovet Market Animal Health for the treatment and control of fascioliasis in livestock. The product contains **triclabendazole**, a benzimidazole anthelmintic with selective activity against **Fasciola hepatica** and related liver flukes, and is used in species including cattle, sheep, goats, horses, and South American camelids. Trivantel has been marketed in oral suspension formulations such as 10% and 15% triclabendazole and is intended to eliminate both immature and mature fluke stages, supporting treatment of acute, subacute, and chronic liver fluke infection.

Brand names: Trivantel
Other names: triclabendazole oral suspension

Targets

FhBT (Fasciola hepatica beta-tubulin)

Beyond the preview

Go deeper on Trivantel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trivantel.

Explore the full profile